STRYKER CORP reported revenue of $6.59B for the period ended 2026-06-30, +9.4% year on year. Net income was $1.28B, a 19.4% net margin on a 68.3% gross margin. The largest revenue line is Medical at 17% of the total. Free cash flow for the period was $1.06B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $6.59B | +9.4% |
| Gross profit | $4.50B | — |
| Operating income | $1.66B | — |
| Net income | $1.28B | +44.3% |
| Gross margin | 68.3% | Net margin 19.4% |
| Revenue Q/Q | +9.5% | — |
| Segment | Revenue | Share |
|---|---|---|
| Medical | $1.12B | 17.0% |
| Traumaand Extremities | $1.07B | 16.3% |
| Endoscopy | $1.00B | 15.2% |
| Instruments | $1.00B | 15.2% |
| Ortho Tech | $0.72B | 10.9% |
| Knees | $0.69B | 10.5% |
| Neurovascular | $0.50B | 7.5% |
| Hips | $0.48B | 7.3% |
| Spinal Implants | $0.00B | 0.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $2.09B | 31.7% |
| R&D | $0.43B | 6.6% |
| SG&A | $2.23B | 33.8% |
| Tax & other | $0.38B | 5.8% |
| Item | Amount |
|---|---|
| Total assets | $47.93B |
| Total liabilities | $23.94B |
| Shareholders' equity | $23.99B |
| Equity / assets | 50.0% |
| Operating cash flow | $1.26B |
| Capital expenditure | $0.20B |
| Free cash flow | $1.06B |
| Cash conversion (OCF / net income) | 99% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
SMCI ・ SYF ・ SNPS ・ SYY ・ TMUS ・ TROW ・ TTWO ・ TPR ・ TRGP ・ TGT ・ TEL ・ TDY
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies